



Pharm-Sintez

Real care about your future

CEO Pharm-Sintez,
Mr. Timofey Petrov

1

Pharm - Sintez



«Pharm – Sintez» is a dynamically developing Russian pharmaceutical company, which comes out with highly effective original/generic medical API's and consumer drug forms




- At «Pharm – Sintez», we also focus on innovative high-tech drugs, for instance in radiological medicine
- We go through research work and synthesis of API's to produce consumer drug forms

2

The nuclear medicine global trend



The world market growth of production and services nuclear medicine
mln, \$ (expert)





Worldwide: Nuclear Medicine / Report D.A. Kovalevich, SC Rosatom, 19/05/2010


The instrumental diagnostics structure trend



Medical Imaging Market:
Percent of
World Revenues by Product
Type 2000



Radio-nuclear bone diagnostics will be 55% of the total number of bone studies towards 2025.



Isotopes based methods will be 48% of the total number of all research activities, covering 26% of PET imaging studies.

Official position of the EANM (European Association of Nuclear Medicine). The medical use of radiopharmaceuticals up to 2025. 2008

Statistic data of cancer in Russia



2.5 million people are observed on Oncology Center
 480 000 are diagnosed new cancers cases every year
 60% of them have III-IV stage

LOW LEVEL OF NUCLEAR MEDICINE IMAGINE

	Real number	Necessity
PET	7	95
SPECT	180	> 300
Nuclear medicine therapy	2000	> 31 000


5

Nuclear medicine service in Russia



- 220 branches of RD
- 180 gamma cameras on hand


- 550 extra gamma-cameras to be installed towards 2013



Based on the nuclear medicine report issued by Russian Health Minister T. Golikova for the Modernization and Technological Development Commission under of Russian President D. Medvedev

6

New trends in the development pharmaceutical industry




Nuclear medicine imaging

Rezscan, ^{99m}Tc (^{99m}Tc -zoledronic acid)



Original radionucler medicine for early diagnostics of tumors' bone metastasis .



Using the Zoledronic acid as a modern carrier for ^{99m}Tc




Patent number 2407746
International Application Number: RST/RU2008 / 000 748 (6314)

Rezoscans, ^{99m}Tc – economic benefits



Scintigraphy 1 hour after the injection of Rezoscans



It is true for both Rezoscans and Traditional RP where a one SPECT tomography is set on a 6 hours / day.

9


Nuclear medicine therapy

ZoleRen (^{188}Re -zoledronic acid)



Innovative therapeutic radionuclear medicine applied for bone metastasis palliative therapy.

THE FIRST AND ORIGINAL RADIOPHARMACEUTICAL METHOD FOR PALLIATIVE THERAPY



SYNERGY OF THE THERAPEUTIC EFFECTS


The new method allows for:

- outpatient therapy
- high-tech therapy in remote areas
- ease of operation
- the use of $^{188}\text{W}/^{188}\text{Re}$ generator


Patent number 2407746

International Application Number: RST/RU2008 / 000 748 (6314)

Medical-diagnostic complex
Skeletal metastases




Medical-diagnostic complex
Algorithm



Nuclear medicine imaging Octreotid, ^{111}In / NeoPET




The original radionucler medicines for tumors diagnostics with high densities of somatostatin receptors.



Application number: 2011113388

Medical-diagnostic complex – Neuroendocrine tumors (NET)



Thank you for your
attention!